华盛昌(002980) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥148,818,081.86, a decrease of 9.49% compared to ¥164,423,521.31 in the same period last year[4] - Net profit attributable to shareholders was ¥25,385,849.65, down 37.36% from ¥40,523,552.79 year-on-year[4] - Operating profit decreased to ¥28,427,318.88 from ¥46,345,690.94, a decline of approximately 38.7%[20] - Net profit for the current period is ¥25,398,014.36, down from ¥40,546,036.69, indicating a decrease of about 37.3%[20] - Total comprehensive income for the current period is ¥25,069,325.71, down from ¥40,474,612.45, indicating a decrease of approximately 38.0%[21] - The basic earnings per share decreased to ¥0.19 from ¥0.30, a decline of about 36.7%[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 178.43% to ¥14,801,980.57, compared to ¥5,316,218.05 in the previous year[4] - The net increase in cash and cash equivalents was -¥48,329,364.77, a decline of 161.25% compared to an increase of ¥78,906,644.97 in the previous year[9] - Cash and cash equivalents at the end of the period decreased to ¥362,580,937.40 from ¥445,744,424.78, a decline of about 18.6%[25] - The company reported a net cash outflow from investing activities of ¥58,572,725.26, compared to a net inflow of ¥78,343,379.99 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,206,519,955.04, a slight increase of 0.84% from ¥1,196,465,650.69 at the end of the previous year[5] - The company's total liabilities decreased to CNY 118,497,641.82 from CNY 134,056,286.50 at the beginning of the year, indicating a reduction of approximately 11.6%[17] - The total current liabilities decreased to CNY 95,529,360.19 from CNY 120,831,373.62, a decrease of approximately 20.9%[16] - Cash and cash equivalents decreased to CNY 363,590,345.73 from CNY 411,919,710.50, representing a decline of approximately 11.7%[15] - The company's inventory increased to CNY 267,637,388.19 from CNY 253,044,261.01, marking an increase of about 5.8%[15] - The accounts receivable decreased to CNY 112,898,277.97 from CNY 124,545,618.26, a reduction of approximately 9.4%[15] Investment and Research - Research and development expenses increased by ¥2,159,000, reflecting a significant investment in innovation[5] - Research and development expenses increased to ¥12,321,559.88 from ¥10,162,534.49, reflecting a rise of approximately 21.2%[20] - Investment income rose by 433.93% to ¥456,841.57, attributed to gains from the disposal of financial products[9] - The company reported a significant increase in intangible assets, rising to CNY 33,652,453.51 from CNY 4,744,547.48, which is an increase of over 608%[16] Future Outlook - The company has plans for future product development and market expansion, focusing on innovative technologies and strategic partnerships[13] - The company received CE certification for its COVID-19 antigen rapid test kit, enhancing its product portfolio and market competitiveness[13]